期刊
JOURNAL OF CLINICAL MEDICINE
卷 10, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/jcm10091841
关键词
autologous stem cell transplantation; clinical study; combination chemotherapy; high dose melphalan therapy; in vitro and in vivo studies; multiple myeloma
资金
- Polish National Centre for Research and Development [POWR.03.02.00-00-I033/16-00]
This review discusses the pharmacokinetics and pharmacodynamics of melphalan therapy in multiple myeloma, as well as its use in innovative treatments such as drug carriers to reduce toxicity, combination therapy to enhance efficacy, and chemical modification to improve antitumor activity.
Multiple myeloma (MM) accounts for 10% of all hematological malignancies, and it is the second most common hematological neoplasm for which chemotherapy is an important pharmacological treatment. High dose melphalan followed by autologous stem cell transplantation remains the standard of treatment for transplant-eligible patients with MM. In this review, we describe aspects of the pharmacokinetics and pharmacodynamics of melphalan therapy and related compounds. In addition, we describe the use of melphalan in innovative therapies for the treatment of MM, including the development of drug carriers to reduce systemic toxicity, combination therapy to improve the effectiveness of cancer therapy, and the chemical modification of the melphalan molecule to improve antitumor activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据